EMA drafts 16 product-specific guidelines for more consistent BE testing
This article was originally published in SRA
Generic drug companies wanting to develop products containing any of 16 pharmaceutical substances should have a clearer idea of how to go about doing so, after the European Medicines Agency released a set of draft product-specific guidelines on demonstrating bioequivalence1.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.